JP2010500370A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010500370A5 JP2010500370A5 JP2009523966A JP2009523966A JP2010500370A5 JP 2010500370 A5 JP2010500370 A5 JP 2010500370A5 JP 2009523966 A JP2009523966 A JP 2009523966A JP 2009523966 A JP2009523966 A JP 2009523966A JP 2010500370 A5 JP2010500370 A5 JP 2010500370A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- huluc63
- ebmt
- administration induces
- remission
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 229960004137 elotuzumab Drugs 0.000 claims 4
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 2
- 229960003957 dexamethasone Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960003433 thalidomide Drugs 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 101710085938 Matrix protein Proteins 0.000 claims 1
- 101710127721 Membrane protein Proteins 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83625006P | 2006-08-07 | 2006-08-07 | |
| US85614406P | 2006-11-01 | 2006-11-01 | |
| PCT/US2007/075401 WO2008019376A2 (en) | 2006-08-07 | 2007-08-07 | Compositions and methods using anti-cs1 antibodies to treat multiple myeloma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013178996A Division JP5775125B2 (ja) | 2006-08-07 | 2013-08-30 | 多発性骨髄腫を処置するための抗ｃｓｉ抗体を用いる組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010500370A JP2010500370A (ja) | 2010-01-07 |
| JP2010500370A5 true JP2010500370A5 (enExample) | 2010-09-30 |
Family
ID=39033619
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009523966A Withdrawn JP2010500370A (ja) | 2006-08-07 | 2007-08-07 | 多発性硬化症を処置するための抗ｃｓ１抗体を用いる組成物および方法 |
| JP2013178996A Active JP5775125B2 (ja) | 2006-08-07 | 2013-08-30 | 多発性骨髄腫を処置するための抗ｃｓｉ抗体を用いる組成物および方法 |
| JP2015074786A Active JP6005205B2 (ja) | 2006-08-07 | 2015-04-01 | 多発性骨髄腫を処置するための抗ｃｓｉ抗体を用いる組成物および方法 |
| JP2016172453A Pending JP2017025077A (ja) | 2006-08-07 | 2016-09-05 | 多発性骨髄腫を処置するための抗ｃｓｉ抗体を用いる組成物および方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013178996A Active JP5775125B2 (ja) | 2006-08-07 | 2013-08-30 | 多発性骨髄腫を処置するための抗ｃｓｉ抗体を用いる組成物および方法 |
| JP2015074786A Active JP6005205B2 (ja) | 2006-08-07 | 2015-04-01 | 多発性骨髄腫を処置するための抗ｃｓｉ抗体を用いる組成物および方法 |
| JP2016172453A Pending JP2017025077A (ja) | 2006-08-07 | 2016-09-05 | 多発性骨髄腫を処置するための抗ｃｓｉ抗体を用いる組成物および方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US7842293B2 (enExample) |
| EP (2) | EP2068930B1 (enExample) |
| JP (4) | JP2010500370A (enExample) |
| AU (1) | AU2007281682B2 (enExample) |
| BR (1) | BRPI0716475A2 (enExample) |
| CA (1) | CA2660102C (enExample) |
| CY (1) | CY1113309T1 (enExample) |
| DK (1) | DK2068930T3 (enExample) |
| ES (1) | ES2391790T3 (enExample) |
| HR (1) | HRP20120934T1 (enExample) |
| IL (1) | IL196920A (enExample) |
| MX (1) | MX2009001440A (enExample) |
| NO (1) | NO345083B1 (enExample) |
| NZ (1) | NZ574979A (enExample) |
| PL (1) | PL2068930T3 (enExample) |
| PT (1) | PT2068930E (enExample) |
| WO (1) | WO2008019376A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007281682B2 (en) | 2006-08-07 | 2013-05-16 | Abbvie Biotherapeutics Inc. | Compositions and methods using anti-CS1 antibodies to treat multiple myeloma |
| PT2068874E (pt) | 2006-08-07 | 2015-05-21 | Abbvie Biotherapeutics Inc | Métodos de tratamento de mieloma múltiplo utilizando terapias de combinação baseadas em anticorpos anti-csi |
| CA3138282A1 (en) * | 2008-06-02 | 2009-12-10 | Dana-Farber Cancer Institute, Inc. | Xbp1, cd138, and cs1 peptides |
| JP2012507555A (ja) * | 2008-10-31 | 2012-03-29 | アボット バイオセラピューティクス コーポレイション | 稀少疾患の治療における抗ｃｓ１抗体の使用 |
| WO2013081612A1 (en) | 2011-11-30 | 2013-06-06 | Abbvie Biotherapeutics Inc. | Vectors and host cells comprising a modified sv40 promoter for protein expression |
| SG11201408679XA (en) | 2012-06-26 | 2015-01-29 | Del Mar Pharmaceuticals | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
| WO2014071402A1 (en) | 2012-11-05 | 2014-05-08 | Dana-Farber Cancer Institute, Inc. | Xbp1, cd138, and cs1, pharmaceutical compositions that include the peptides, and methods of using such petides and compositions |
| US11491154B2 (en) | 2013-04-08 | 2022-11-08 | Dennis M. Brown | Therapeutic benefit of suboptimally administered chemical compounds |
| WO2015069785A1 (en) | 2013-11-06 | 2015-05-14 | Bristol-Myers Squibb Company | Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma |
| WO2015069703A1 (en) | 2013-11-06 | 2015-05-14 | Bristol-Myers Squibb Company | Immunotherapeutic dosing regimens and combinations thereof |
| AU2015339012B2 (en) * | 2014-10-31 | 2020-11-05 | Abbvie Biotherapeutics Inc. | Anti-CS1 antibodies and antibody drug conjugates |
| AU2015358462A1 (en) | 2014-12-04 | 2017-07-27 | Bristol-Myers Squibb Company | Combination of anti-CS1 and anti-PD1 antibodies to treat cancer (myeloma) |
| LT3313528T (lt) | 2015-06-29 | 2021-10-11 | Bristol-Myers Squibb Company | Imunoterapinės dozavimo schemos, apimančios pomalidomidą ir anti-cs1 antikūną, skirtos vėžio gydymui |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
| CN115298549A (zh) | 2019-11-05 | 2022-11-04 | 百时美施贵宝公司 | M蛋白测定及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL112969A (en) | 1994-03-17 | 2001-05-20 | Baxter Int | Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator |
| DE69633668T2 (de) | 1995-05-25 | 2006-03-09 | Shimon Slavin | Allogene zelltherapie für krebs infolge allogener stammzellen transplantation |
| US7709610B2 (en) * | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
| US20050025763A1 (en) * | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| US20080095768A1 (en) | 2006-08-07 | 2008-04-24 | Pdl Biopharma, Inc. | Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells |
| AU2007281682B2 (en) * | 2006-08-07 | 2013-05-16 | Abbvie Biotherapeutics Inc. | Compositions and methods using anti-CS1 antibodies to treat multiple myeloma |
| PT2068874E (pt) | 2006-08-07 | 2015-05-21 | Abbvie Biotherapeutics Inc | Métodos de tratamento de mieloma múltiplo utilizando terapias de combinação baseadas em anticorpos anti-csi |
-
2007
- 2007-08-07 AU AU2007281682A patent/AU2007281682B2/en active Active
- 2007-08-07 PL PL07840744T patent/PL2068930T3/pl unknown
- 2007-08-07 DK DK07840744.2T patent/DK2068930T3/da active
- 2007-08-07 EP EP07840744A patent/EP2068930B1/en active Active
- 2007-08-07 HR HRP20120934TT patent/HRP20120934T1/hr unknown
- 2007-08-07 BR BRPI0716475A patent/BRPI0716475A2/pt not_active Application Discontinuation
- 2007-08-07 US US11/835,245 patent/US7842293B2/en active Active
- 2007-08-07 JP JP2009523966A patent/JP2010500370A/ja not_active Withdrawn
- 2007-08-07 NZ NZ574979A patent/NZ574979A/en unknown
- 2007-08-07 WO PCT/US2007/075401 patent/WO2008019376A2/en not_active Ceased
- 2007-08-07 MX MX2009001440A patent/MX2009001440A/es active IP Right Grant
- 2007-08-07 CA CA2660102A patent/CA2660102C/en active Active
- 2007-08-07 EP EP11176209A patent/EP2425849A3/en not_active Withdrawn
- 2007-08-07 PT PT07840744T patent/PT2068930E/pt unknown
- 2007-08-07 ES ES07840744T patent/ES2391790T3/es active Active
-
2009
- 2009-02-05 IL IL196920A patent/IL196920A/en active Protection Beyond IP Right Term
- 2009-03-03 NO NO20090969A patent/NO345083B1/no unknown
-
2010
- 2010-10-12 US US12/903,051 patent/US20110165154A1/en not_active Abandoned
-
2012
- 2012-10-31 CY CY20121101037T patent/CY1113309T1/el unknown
-
2013
- 2013-08-30 JP JP2013178996A patent/JP5775125B2/ja active Active
-
2015
- 2015-04-01 JP JP2015074786A patent/JP6005205B2/ja active Active
-
2016
- 2016-04-06 US US15/091,977 patent/US20160206734A1/en not_active Abandoned
- 2016-09-05 JP JP2016172453A patent/JP2017025077A/ja active Pending